Evaluation of the efficacy of a posaconazole and anidulafungin combination in a murine model of pulmonary aspergillosis due to infection with Aspergillus fumigatus

Publication date: Available online 12 October 2017
Source:Diagnostic Microbiology and Infectious Disease
Author(s): Laura Bedin Denardi, Francielli Pantella Kunz de Jesus, Jéssica Tairine Keller, Carla Weiblen, Maria Isabel de Azevedo, Vanessa Oliveira, Janio Morais Santurio, Sydney Hartz Alves
Posaconazole (PSC) in combination with anidulafungin (AFG) was evaluated in a murine model of pulmonary aspergillosis. Immunosuppressed animals were infected via the nasal cavity with two different A. fumigatus strains. The animals received PSC (oral, 20mg/kg/day) and/or AFG (i.p., 10mg/kg/day) for 7days. On day 8, the mice were euthanized and fungal burdens were determined from the lungs. Survival curves were constructed for mortality analysis. Compared to untreated groups, groups singly treated with PSC or AFG showed a reduced fungal burden in the lungs (P=0.0001–0.006) and prevention of mortality (66.66% to 83.33% of survival). Combination treatment with PSC and AFG significantly reduced the fungal burden (or sterilized the lungs) compared to the findings in the untreated and monotherapy groups and improved the survival rate to 100%. The PSC and AFG combination therapy was highly effective and should be evaluated in larger-scale experiments.



from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2yH8xBZ
via IFTTT